Compare DV & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | COAG |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2026 |
| Metric | DV | COAG |
|---|---|---|
| Price | $11.45 | $48.77 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $16.37 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 245.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $748,291,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | $295.88 | ★ N/A |
| Revenue Growth | ★ 13.92 | N/A |
| 52 Week Low | $7.61 | $27.47 |
| 52 Week High | $16.82 | $45.27 |
| Indicator | DV | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 73.98 |
| Support Level | $10.76 | $28.51 |
| Resistance Level | $11.58 | N/A |
| Average True Range (ATR) | 0.42 | 4.26 |
| MACD | 0.01 | 1.57 |
| Stochastic Oscillator | 55.29 | 93.46 |
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.